Michael Shetzline Ironwood Pharmaceuticals Inc (IRWD) insider trading activity

IRWD Quotes by TradingView

Michael Shetzline is SVP, CMO, Head-Res&Drug of IRONWOOD PHARMACEUTICALS INC. Currently has a direct ownership of 554,007 shares of IRWD, which is worth approximately $853,170. The most recent transaction as insider was on Feb 10, 2025, when has been sold 41,269 shares (Class A Common Stock) at a price of $1.76 per share, resulting in proceeds of $72,633. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 554K
33.91% 3M change
28.88% 12M change
Total Value Held $853,170

Michael Shetzline Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 10 2025
SELL
Open market or private sale
$72,633 $1.76 p/Share
41,269 Reduced 6.93%
554,007 Class A Common Stock
Feb 10 2025
BUY
Grant, award, or other acquisition
-
133,333 Added 18.3%
595,276 Class A Common Stock
Jan 17 2025
BUY
Grant, award, or other acquisition
-
48,224 Added 9.45%
461,943 Class A Common Stock
May 20 2024
SELL
Open market or private sale
$104,025 $6.45 p/Share
16,128 Reduced 3.75%
413,719 Class A Common Stock
Mar 08 2024
BUY
Exercise of conversion of derivative security
-
34,936 Added 7.52%
429,847 Class A Common Stock
Feb 12 2024
SELL
Open market or private sale
$588,538 $15.24 p/Share
38,618 Reduced 10.19%
340,484 Class A Common Stock
Feb 12 2024
BUY
Grant, award, or other acquisition
-
54,427 Added 12.11%
394,911 Class A Common Stock
Jan 17 2024
BUY
Grant, award, or other acquisition
-
57,971 Added 13.26%
379,102 Class A Common Stock
May 22 2023
SELL
Open market or private sale
$104,478 $10.12 p/Share
10,324 Reduced 3.11%
321,131 Class A Common Stock
Mar 08 2023
BUY
Grant, award, or other acquisition
-
69,869 Added 17.41%
331,455 Class A Common Stock
Feb 28 2023
SELL
Open market or private sale
$111,448 $11.31 p/Share
9,854 Reduced 3.63%
261,586 Class A Common Stock
Feb 27 2023
SELL
Open market or private sale
$108,029 $11.41 p/Share
9,468 Reduced 3.37%
271,440 Class A Common Stock
Jan 17 2023
BUY
Grant, award, or other acquisition
-
14,663 Added 4.96%
280,908 Class A Common Stock
May 23 2022
SELL
Open market or private sale
$121,704 $11.5 p/Share
10,583 Reduced 3.82%
266,245 Class A Common Stock
Mar 02 2022
BUY
Grant, award, or other acquisition
-
81,448 Added 22.73%
276,828 Class A Common Stock
Feb 28 2022
SELL
Open market or private sale
$189,627 $10.77 p/Share
17,607 Reduced 8.27%
195,380 Class A Common Stock
Jan 19 2022
BUY
Grant, award, or other acquisition
-
29,326 Added 12.1%
212,987 Class A Common Stock
Nov 23 2021
SELL
Open market or private sale
$159,526 $11.58 p/Share
13,776 Reduced 6.98%
183,661 Class A Common Stock
May 24 2021
SELL
Open market or private sale
$25,443 $12.25 p/Share
2,077 Reduced 1.04%
197,437 Class A Common Stock
Mar 26 2021
BUY
Grant, award, or other acquisition
-
38,655 Added 16.23%
199,514 Class A Common Stock
Feb 26 2021
SELL
Open market or private sale
$40,439 $9.11 p/Share
4,439 Reduced 2.69%
160,859 Class A Common Stock
Feb 22 2021
BUY
Grant, award, or other acquisition
-
58,252 Added 26.06%
165,298 Class A Common Stock
MS

Michael Shetzline

SVP, CMO, Head-Res&Drug
Boston, MA

Track Institutional and Insider Activities on IRWD

Follow IRONWOOD PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells IRWD shares.

Notify only if

Insider Trading

Get notified when an Ironwood Pharmaceuticals Inc insider buys or sells IRWD shares.

Notify only if

News

Receive news related to IRONWOOD PHARMACEUTICALS INC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on IRWD